Investigation of Pharmacokinetics, Safety and Tolerability of Multiple Subcutaneous Doses of NNC0519-0130 in Male Chinese Participants With Overweight or Obesity
Latest Information Update: 11 Jun 2025
At a glance
- Drugs NNC 0519 0130 (Primary)
- Indications Obesity; Overweight
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
Most Recent Events
- 11 Jun 2025 New trial record